Biotechnology Weekly Update - 10-August-2023

Dovital uw gezondheid- en vitaliteitbevorderende producten
21 Bekeken
FDA approves First Ever Drug To Treat Postpartum Depression
Sage Therapeutics/Biogen’s Zurzuvae has received FDA approval for postpartum depression, a mood disorder affecting 13% to 20% of women in the postpartum period.

BioNTech Trims R&D Expenses
BioNTech is tightening its R&D expenses this year in response to disappointing Q2 results due to lower COVID-19 vaccine market demand and write-offs by Pfizer.

Obesity Drug Cuts Risk Of Stroke, Heart Attack by 20% in Landmark Study
Novo Nordisk's obesity drug Wegovyv demonstrated 20% reduction in major adverse cardiovascular events in a landmark heart health study, dubbed SELECT.

FDA Approves New Treatment For Geographic Atrophy
Astellas’ Izervay has secured FDA approval for treating geographic atrophy. The drug is anticipated to be available in the US in two to four weeks.,-a-New-Treatment-for-Geographic-Atrophy

Emergent BioSolutions To Cut 400 Jobs
Emergent BioSolutions is reducing its workforce by roughly 400 employees, as part of its strategic steps to strengthen core business and financial position.

Subscribe to RTT Biotech Investor to get timely updates on Biotech & Pharma industry, and access all the timely news, time-sensitive information, and alerts that can enable you to make sound investment decisions.

Follow us on
Instagram -
YouTube -

#biotech #biotechnology #rttnews #FDA #obesity #biontech #weeklyupdate #jobcuts
Log in of aanmelden om een reactie te plaatsen.
Wees de eerste die een reactie plaatst.